• Mithramycin A: Workflow for Transcription Studies

  2026-08-23

  Mithramycin A is an anticancer antibiotic for probing G-C-rich DNA regulation, c-myc suppression, and myeloid differentiation in cancer models. This practical guide connects dosing, transcriptional readouts, HL-60 assays, and the miR-24-3p/Sp1/PI3K findings from a cardiac injury study without overstating cross-domain evidence.

• Trametinib (GSK1120212): MEK-ERK Research Guide

  2026-08-22

  Trametinib, also known as GSK1120212, is an ATP-noncompetitive MEK1/2 inhibitor for controlled studies of MAPK signaling. Its reported biochemical potency, G1 arrest activity, and B-RAF-mutant model sensitivity support its use as an oncology research tool, while recent stem-cell evidence links MEK/ERK inhibition to TERT repression.

• DOM Biphasic Responses: 5-HT2C/1A Modulation

  2026-08-22

  This 2024 mouse study separates the receptor mechanisms controlling DOM-induced head twitch response from those shaping locomotor activity across an inverted U-shaped dose curve. Its pharmacological evidence indicates persistent 5-HT2A dependence for head twitch behavior, with 5-HT2C, 5-HT1A, and Gαi/o-sensitive mechanisms contributing differently to locomotor responses.

• Alosetron in Intestinal Polarity Research

  2026-08-21

  Alosetron provides a selective, reversible way to test whether 5-HT3 receptor input modifies intestinal epithelial behavior without replacing genetic polarity models. This workflow connects serotonin receptor pharmacology with organoid, monolayer, and ex vivo assays of YAP-EGFR-mTOR signaling, stem-cell fate, motility, and visceral pain-related biology.

• Clarithromycin CYP3A Inhibition Workflows

  2026-08-20

  Build reproducible CYP3A inhibition assays with Clarithromycin for statin metabolism interaction, cardiovascular drug interaction, and broader drug-drug interaction research. This workflow pairs solvent-aware preparation with a pathway-negative dabigatran comparator to separate CYP3A effects from non-CYP disposition.

• Carbenoxolone disodium: Practical Protocol Guide

  2026-08-20

  Carbenoxolone disodium is a research tool for probing 11β-hydroxysteroid dehydrogenase activity, corticosterone metabolism, and gap junction communication in cell- and tissue-based workflows. It is useful for mechanistic experiments but should not be treated as a selective in vivo efficacy agent or a probe with strict off-target control.

• Baicalin Workflows for Adult Visual Plasticity

  2026-08-19

  Baicalin offers a defined small-molecule workflow for testing adult ocular dominance plasticity, with optical imaging, electrophysiology, and cortical inhibition assays providing complementary endpoints. Its distinct solubility and stability profile also supports carefully controlled cancer research applications, including KEAP1-NRF2/HO-1 pathway modulation and TGF-β1/p-Smad3 pathway inhibition.

• Metformin Hydrochloride: HO Research Workflows

  2026-08-19

  Learn how Metformin Hydrochloride supports reproducible studies of glucose metabolism, AMPK signaling, and tendon heterotopic ossification. This workflow translates Nr4a1/Wnt/β-catenin findings into practical cell-based, molecular, and preclinical assay decisions.

• Deferoxamine mesylate in cell assays

  2026-08-18

  A practical, scenario-based guide to using Deferoxamine mesylate (SKU B6068) to control iron availability, oxidative stress, and hypoxia signaling in viability, proliferation, and cytotoxicity workflows. It covers assay controls, solution preparation, interpretation, and evidence-based product selection.

• TPPU and the Liver–Bone Axis of sEH

  2026-08-18

  TPPU offers a precise way to interrogate soluble epoxide hydrolase, fatty acid epoxide signaling, and the emerging liver–bone axis linking lipid metabolism, redox control, and osteoclastogenesis.

• HNF4A-AS1 Reprograms Lipid Metabolism in Sorafenib Resistanc

  2026-08-17

  A 2024 Theranostics study identifies the liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib sensitivity in hepatocellular carcinoma. The work connects HNF4A-AS1, METTL3-mediated m6A modification, DECR1 mRNA stability, PUFA abundance, and ferroptosis, offering a mechanistic explanation for one form of treatment resistance.

• Palonosetron Dissociation Kinetics at 5-HT3 Receptors

  2026-08-17

  Lummis and Thompson showed that palonosetron displays ligand-dependent dissociation kinetics at both 5-HT3A and 5-HT3AB receptors, with agonists producing markedly slower dissociation than antagonists. The study combines functional FlexStation measurements, radioligand binding, and kinetic analysis to explain why receptor-level persistence may contribute to palonosetron’s prolonged pharmacological action.

• Ferrostatin-1: A Causal Ferroptosis Assay Tool

  2026-08-16

  Ferrostatin-1 and Fer-1 provide a powerful rescue strategy for distinguishing ferroptosis from nonspecific oxidative injury. This article translates brazilin breast cancer findings into practical assay design, interpretation, and cross-model validation.

• Tofacitinib Reprograms RA Macrophage Metabolism

  2026-08-15

  A 2026 study shows that Tofacitinib reverses the inflammatory, oxidative, and mitochondrial abnormalities induced by GM-CSF in rheumatoid arthritis macrophages. Its comparative human and murine experiments distinguish broad STAT5-associated pathway correction from metabolic interventions that produced narrower effects.

• Modeling Breast Cancer Relapse with Proliferation Tracing

  2026-08-14

  The reference study introduces a dual recombinase proliferation-tracing and ablation system in spontaneous MMTV-PyMT mammary tumors. Acute removal of recently proliferating cells produced tumor regression followed by relapse from low-cycling reservoirs, while single-cell RNA sequencing revealed recurrent tumors enriched for stem-like cancer cells and protumor immune and myeloid states.

8387 records 1/560 page Next 12345 下5页 Last page